UCB (STU:UNC) Accounts Payable: €817 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
90 GF Score
Price €239.20
GF Value €211.82
Valuation Modestly Overvalued
View Full Analysis

What is UCB Accounts Payable?

UCB STU:UNC +1.01% 90 Accounts Payable is €817 Mil as of Dec. 2025. GuruFocus rates STU:UNC with a GF Score™ of 90/100 and a GF Value™ of €211.82 (Modestly Overvalued).

UCB's Accounts Payable for the quarter that ended in Dec. 2025 was €817 Mil.

UCB's quarterly Accounts Payable increased from Dec. 2024 (€750 Mil) to Jun. 2025 (€3,197 Mil) but then declined from Jun. 2025 (€3,197 Mil) to Dec. 2025 (€817 Mil).

UCB's annual Accounts Payable increased from Dec. 2023 (€537 Mil) to Dec. 2024 (€750 Mil) and increased from Dec. 2024 (€750 Mil) to Dec. 2025 (€817 Mil).

UCB Accounts Payable Historical Data

* Premium members only.

The historical data trend for UCB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Accounts Payable Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 596.00 573.00 537.00 750.00 817.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 537.00 2,415.00 750.00 3,197.00 817.00
STU:UNC
90GF Score
UCB SA STU:UNC
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €817 Mil mean?
UCB (STU:UNC) has a Accounts Payable of €817 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on UCB and its competitors.
Is UCB's Accounts Payable too high?
UCB's current Accounts Payable is €817 Mil. Overall, UCB has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Accounts Payable compare to VRTX and REGN?
UCB's Accounts Payable of €817 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on UCB and its competitors. UCB's current Accounts Payable is €817 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.82, compared to a current price of €239.20 — trading 12.9% above its estimated fair value. The current Accounts Payable is €817 Mil. UCB's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For UCB (STU:UNC), the current Accounts Payable is €817 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €239.20 is trading 12.9% above its estimated GF Value™ of €211.82. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Accounts Payable: €817 Mil
  • GF Value™: €211.82 vs. price of €239.20 (12.9% above fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score

Get the complete analysis for STU:UNC

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€239.20
Price
€211.82
GF Value